When a safe and effective COVID-19 vaccine is developed, will it be a “peoples vaccine” produced in time and scale, affordably priced, and available for all countries and all people? This will not be possible if the vaccines are produced and distributed under the prevailing market model of private finance and monopoly protection. As world leaders commit to ensuring equitable access to vaccines, treatment, and diagnostics, what are the politics of negotiations amongst governments, industry, financing agencies, and public health institutions health equity activists on a new model of financing, production, and patent protection? How are the Global South and civil society groups engaging, and how are their voices being heard?
• Sakiko-Fukuda Parr, Professor and Director of the Julien J. Studley Graduate Programs in International Affairs
• Mariângela Simão, Assistant Director-General for Access to Medicines, Vaccines and Pharmaceuticals, World Health Organization
• Celso Amorim, Minister of External Relations of Brazil (1993-94; 2003-2010), and Minister of Defense of Brazil (2011-2014)
• Ellen t’Hoen, Director of Medicines Law & Policy, researcher at the University of Groningen and founder of the Medicines Patent Pool
• Achal Prabhala, Shuttleworth Fellow in advancing innovation and access to medicines and co-coordinator of AccessIBSA
• Elen Høeg, Policy Manager, CEPI (Coalition for Epidemic Preparedness Innovations)
Click here to watch the full webinar.